Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16107540 | 1.00 | NAAA (0.55) | NAAASMN1; SMN2ALDH1A1EPHX1HTT | |
| SCHEMBL9780637 | 0.98 | NAAA (0.57) | NAAASMN1; SMN2ALDH1A1EPHX1HTT | |
| SCHEMBL5243467 | 0.98 | NAAA (0.57) | NAAASMN1; SMN2ALDH1A1EPHX1HTT | |
| SCHEMBL6126665 | 0.98 | NAAA (0.57) | NAAASMN1; SMN2ALDH1A1EPHX1HTT | |
| SCHEMBL11348786 | 0.98 | NAAA (0.57) | NAAASMN1; SMN2ALDH1A1EPHX1HTT | |
| SCHEMBL3404981 | 0.98 | NAAA (0.57) | NAAASMN1; SMN2ALDH1A1EPHX1HTT | |
| SCHEMBL11531764 | 0.98 | NAAA (0.57) | NAAASMN1; SMN2ALDH1A1EPHX1HTT | |
| SCHEMBL11348782 | 0.98 | NAAA (0.57) | NAAASMN1; SMN2ALDH1A1EPHX1HTT | |
| SCHEMBL11349018 | 0.95 | SMN1; SMN2 (0.56) | NAAASMN1; SMN2ALDH1A1HTTPOLB | |
| SCHEMBL12159279 | 0.95 | SMN1; SMN2 (0.56) | NAAASMN1; SMN2ALDH1A1HTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107207510-B | Conjoint therapy | 诺华股份有限公司 | 2019-11-29 | — | — | CN | disclosed |
| CN-105377288-B | Use of a combination of XBP1, CD138 and CS1 peptides for the preparation of a medicament | 达纳-法伯癌症研究所股份有限公司 | 2019-11-15 | — | — | CN | disclosed |
| CN-105452235-B | Substituted quinazoline-4-one derivatives | 诺华股份有限公司 | 2019-08-09 | — | — | CN | disclosed |
| CN-109641838-A | CXCR4 inhibitor and application thereof | X4 制药有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109640988-A | CXCR4 inhibitors and uses thereof | X4 制药有限公司 | 2019-04-16 | — | — | CN | disclosed |
| CN-109562106-A | CXCR4 inhibitors and uses thereof | X4 制药有限公司 | 2019-04-02 | — | — | CN | disclosed |
| WO-2018169700-A1 | SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2018-09-20 | — | — | WO | disclosed |
| EP-3174869-A1 | COMBINATION THERAPY | Novartis AG (CH) | 2017-06-07 | — | — | EP | disclosed |
| CN-106470681-A | Supramolecular assembly medicine | 茵维特丝肿瘤学私营有限责任公司 | 2017-03-01 | — | — | CN | disclosed |
| WO-2016205566-A1 | FZD7 SPECIFIC ANTIBODIES AND VACCINES TO TREAT CANCER AND CONTROL STEM CELL FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-12-22 | — | — | WO | disclosed |
| CN-1909908-A | Pyrazolo [1, 5-a ] pyrimidin-7-yl-amine derivatives for the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2007-02-07 | — | — | CN | disclosed |
| CN-1902200-A | 1h-imidazoquinoline derivatives as protein kinase inhibitors | NOVARTIS AG (CH) | 2007-01-24 | — | — | CN | disclosed |
| CN-1882586-A | 1H-imidazo[4,5-C]quinoline derivatives in the treatment of protein kinase dependent diseases | NOVARTIS AG (CH) | 2006-12-20 | — | — | CN | disclosed |
| CN-1283240-C | Pharmaceutical use of COX-2 inhibitors in angiogenesis-mediated ocular disorders | NOVARTIS AG (CH) | 2006-11-08 | — | — | CN | disclosed |
| CN-1856326-A | Combinations of a VEGF receptor inhibitor with other therapeutic agents | NOVARTIS AG (CH) | 2006-11-01 | — | — | CN | disclosed |
| CN-1856327-A | Combination of a VEGF receptor inhibitor with a chemotherapeutic agent | NOVARTIS AG (CH) | 2006-11-01 | — | — | CN | disclosed |
| CN-1649576-A | Methods and compositions for treatment of cancer pain | NOVARTIS AG (CH) | 2005-08-03 | — | — | CN | disclosed |
| CN-1620288-A | Pharmaceutical use of COX-2 inhibitors in angiogenesis-mediated ocular disorders | NOVARTIS AG (CH) | 2005-05-25 | — | — | CN | disclosed |
| CN-1578674-A | Cyclooxygenase-2 inhibitor/histone deacetylase inhibitor combination | NOVARTIS AG (CH) | 2005-02-09 | — | — | CN | disclosed |
| CN-1575168-A | Combinations comprising selective cyclooxygenase-2 inhibitors | NOVARTIS AG (CH) | 2005-02-02 | — | — | CN | disclosed |